Chevy Chase Trust Holdings LLC Sells 9,383 Shares of Amgen Inc. $AMGN

Chevy Chase Trust Holdings LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 280,645 shares of the medical research company’s stock after selling 9,383 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Amgen were worth $79,198,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Circle Wealth Management LLC grew its holdings in shares of Amgen by 7.7% during the third quarter. Circle Wealth Management LLC now owns 1,570 shares of the medical research company’s stock valued at $443,000 after buying an additional 112 shares during the last quarter. Clark Capital Management Group Inc. raised its holdings in shares of Amgen by 19.8% in the 3rd quarter. Clark Capital Management Group Inc. now owns 1,103 shares of the medical research company’s stock worth $311,000 after acquiring an additional 182 shares during the last quarter. Community Bank N.A. lifted its position in Amgen by 1.0% in the 3rd quarter. Community Bank N.A. now owns 16,270 shares of the medical research company’s stock valued at $4,591,000 after acquiring an additional 161 shares in the last quarter. Ausdal Financial Partners Inc. lifted its position in Amgen by 32.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 3,307 shares of the medical research company’s stock valued at $933,000 after acquiring an additional 801 shares in the last quarter. Finally, Azimuth Capital Investment Management LLC boosted its stake in Amgen by 0.7% during the 3rd quarter. Azimuth Capital Investment Management LLC now owns 18,712 shares of the medical research company’s stock valued at $5,281,000 after purchasing an additional 127 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on AMGN shares. HSBC reissued a “buy” rating and set a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Piper Sandler upped their price target on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Guggenheim increased their price target on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $354.00.

Amgen Price Performance

Amgen stock opened at $366.21 on Friday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company’s 50 day moving average price is $357.73 and its two-hundred day moving average price is $325.42. The stock has a market cap of $197.41 billion, a P/E ratio of 25.74, a P/E/G ratio of 3.63 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.